The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment

被引：0
|
作者：
Li, Jisheng
Zhao, Wen
Li, Hongxin
Xuan, Tiantian
Wang, Chengjun
Zhang, Rongyu
Yang, Chuang
Wang, Jian
Yi, Cuihua
机构：
[1] Shandong Univ, Qilu Hosp, Dept Med Oncol, Cheeloo Coll Med, Jinan, Peoples R China
[2] Shandong Univ, Sch Pharmaceut Sci, Cheeloo Coll Med, Jinan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20619
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [2] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Alos-Alminana, Manuel
    Cortijo, Julio
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) : 853 - 863
  • [3] Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Cortijo, Julio
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (04) : 325 - 335
  • [4] Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
    Wang, Hao
    Zeng, Chenxin
    Li, Xin
    Wang, Youjie
    Li, Xinyi
    Ge, Weihong
    [J]. FUTURE ONCOLOGY, 2019, 15 (02) : 181 - 191
  • [5] cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer
    Zhang, Huahua
    Zheng, Xiaochun
    Zhang, Yandong
    Wang, Jiangfeng
    [J]. FUTURE ONCOLOGY, 2024,
  • [6] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [7] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [8] Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer
    Zhang, Xiaojuan
    Zhang, Mina
    Du, Xinyang
    Zhang, Guowei
    Niu, Yuanyuan
    Wei, Chunhua
    Guo, Lanwei
    Shi, Chao
    Liu, Hangfan
    Wang, Huijuan
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [9] Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis
    Haeussler, Katrin
    Wang, Xuan
    Winfree, Katherine B.
    D'yachkova, Yulia
    Traore, Sory
    Puri, Tarun
    Thom, Howard
    Papagiannopoulos, Christos
    Nassim, Maria
    Taipale, Kaisa
    [J]. FUTURE ONCOLOGY, 2022, 18 (16) : 2007 - 2028
  • [10] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
    Soria, J. -C.
    Ohe, Y.
    Vansteenkiste, J.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Imamura, F.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cho, B. C.
    Cheng, Y.
    Cho, E. K.
    Voon, P. J.
    Planchard, D.
    Su, W. -C.
    Gray, J. E.
    Lee, S. -M.
    Hodge, R.
    Marotti, M.
    Rukazenkov, Y.
    Ramalingam, S. S.
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 113 - 125
12345